24 April 2017 ORYZON Announces New Grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug
3 April 2017 ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases
20 March 2017 Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum
15 March 2017 ORYZON to Present at the 11th Annual BIO-Europe Spring International Partnering Conference
27 February 2017 ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017
24 February 2017 ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016